RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis

<p>Abstract</p> <p>Background</p> <p>Epigenetic silencing of the RAS association domain family 1A (<it>RASSF1A</it>) tumor suppressor gene promoter has been demonstrated in renal cell carcinoma (RCC) as a result of promoter hypermethylation. Contradictory results have been reported for <it>RASSF1A </it>methylation in normal kidney, thus it is not clear whether a significant difference between <it>RASSF1A </it>methylation in normal and tumor cells of the kidney exists. Moreover, RASSF1A expression has not been characterized in tumors or normal tissue as yet.</p> <p>Results</p> <p>Using combined bisulfite restriction analysis (COBRA) we compared RASSF1A methylation in 90 paired tissue samples obtained from primary kidney tumors and corresponding normal tissue. Bisulfite sequence analysis was carried out using both pooled amplicons from the tumor and normal tissue groups and subclones obtained from a single tissue pair. Expression of RASSF1A was analyzed by the use of tissue arrays and immunohistochemistry. We found significantly increased methylation in tumor samples (mean methylation, 20%) compared to corresponding normal tissues (mean methylation, 11%; <it>P </it>< 0.001). Densely methylated sequences were found both in pooled and individual sequences of normal tissue. Immunohistochemical analysis revealed a significant reduced expression of RASSF1A in most of the tumor samples. Heterogeneous expression patterns of RASSF1A were detected in a subgroup of histologically normal tubular epithelia.</p> <p>Conclusion</p> <p>Our methylation and expression data support the hypothesis that <it>RASSF1A </it>is involved in early tumorigenesis of renal cell carcinoma.</p

Promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis-1

<p><b>Copyright information:</b></p><p>Taken from "promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis"</p><p>http://www.molecular-cancer.com/content/6/1/49</p><p>Molecular Cancer 2007;6():49-49.</p><p>Published online 16 Jul 2007</p><p>PMCID:PMC1939711.</p><p></p>ylated (M) and unmethylated (U) band signals: L, length marker; C1, negative methylation control (plasmid pCU); C2, positive methylation control (plasmid pCM); CO, negative control; T1 – T3, tumoral and P1 – P3, normal paired tissue samples

Promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis-3

<p><b>Copyright information:</b></p><p>Taken from "promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis"</p><p>http://www.molecular-cancer.com/content/6/1/49</p><p>Molecular Cancer 2007;6():49-49.</p><p>Published online 16 Jul 2007</p><p>PMCID:PMC1939711.</p><p></p> 50 clones analyzed by the use of bisulfite sequencing. For each clone the methylation status of analyzed CpG sites is shown (solid circles: methylation, open circles: no methylation). Numbers on x-axis refer to base pair positions as indicated in Figure 1. Asterisks indicate amplicons derived from densely methylated promoters demonstrating at least 11 methylated CpG sites

Promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis-5

<p><b>Copyright information:</b></p><p>Taken from "promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis"</p><p>http://www.molecular-cancer.com/content/6/1/49</p><p>Molecular Cancer 2007;6():49-49.</p><p>Published online 16 Jul 2007</p><p>PMCID:PMC1939711.</p><p></p>SSF1A protein using immunohistochemistry (counterstaining hematoxylin). a. Immunohistochemical positive control: CaSki cell line demonstrating absence of promoter methylation in COBRA (see box; U, unmethylated signals; M, methylation signals) and immunopositivity depending on the absence () or presence () of an antibody blocking peptide, respectively. b. Immunohistochemical negative control: HEK293 cell line showing strong methylation in COBRA (see box; U, unmethylated signals; M, methylation signals). Only residual unspecific nuclear immunopositivity can be observed, which is independent from the absence () and presence () of an antibody blocking peptide. c. Tumor cells of a clear cell RCC (magnification, 400×). d. Histopathologically normal tissue with immunopositive epithelial tubular cells (magnification, 400×). e. Heterogeneous staining patterns demonstrating immunopositive () and -negative () epithelia in renal tubules. f. Mosaic-like staining signals in a single tubular epithelium (see arrows, magnified from panel d as indicated)

Promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis-8

<p><b>Copyright information:</b></p><p>Taken from "promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis"</p><p>http://www.molecular-cancer.com/content/6/1/49</p><p>Molecular Cancer 2007;6():49-49.</p><p>Published online 16 Jul 2007</p><p>PMCID:PMC1939711.</p><p></p>COBRA in 45 tumor and paired normal renal tissue samples as well as plasmid – DNA negative controls. Note that 44 (98%) tumors and 44 (98%) of 45 paired normal tissues demonstrated relative methylation greater than 2.75% determined as limit of analytical sensitivity. b. Quantitative methylation analysis of the promoter in 45 tumoral and normal tissue pairs using combined bisulfite restriction analysis (COBRA). Note that most of the tumors demonstrate a substantial relative increase in methylation when compared to their corresponding normal tissue (< 0.001

Promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis-6

<p><b>Copyright information:</b></p><p>Taken from "promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis"</p><p>http://www.molecular-cancer.com/content/6/1/49</p><p>Molecular Cancer 2007;6():49-49.</p><p>Published online 16 Jul 2007</p><p>PMCID:PMC1939711.</p><p></p>e sequence analysis. Numbers refer to the position of transcription start site while bracketed numbers indicate CpG sites. Solid triangles show TaqI restrictions sites used for COBRA. The solid and dashed lines indicate sequences amplified for COBRA and sequence analysis following bisulfite conversion of DNA. Inner primer positions were indicated by solid arrows

Promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis-2

<p><b>Copyright information:</b></p><p>Taken from "promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis"</p><p>http://www.molecular-cancer.com/content/6/1/49</p><p>Molecular Cancer 2007;6():49-49.</p><p>Published online 16 Jul 2007</p><p>PMCID:PMC1939711.</p><p></p>COBRA in 45 tumor and paired normal renal tissue samples as well as plasmid – DNA negative controls. Note that 44 (98%) tumors and 44 (98%) of 45 paired normal tissues demonstrated relative methylation greater than 2.75% determined as limit of analytical sensitivity. b. Quantitative methylation analysis of the promoter in 45 tumoral and normal tissue pairs using combined bisulfite restriction analysis (COBRA). Note that most of the tumors demonstrate a substantial relative increase in methylation when compared to their corresponding normal tissue (< 0.001

Promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis-7

<p><b>Copyright information:</b></p><p>Taken from "promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis"</p><p>http://www.molecular-cancer.com/content/6/1/49</p><p>Molecular Cancer 2007;6():49-49.</p><p>Published online 16 Jul 2007</p><p>PMCID:PMC1939711.</p><p></p>ylated (M) and unmethylated (U) band signals: L, length marker; C1, negative methylation control (plasmid pCU); C2, positive methylation control (plasmid pCM); CO, negative control; T1 – T3, tumoral and P1 – P3, normal paired tissue samples

Promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis-4

<p><b>Copyright information:</b></p><p>Taken from "promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis"</p><p>http://www.molecular-cancer.com/content/6/1/49</p><p>Molecular Cancer 2007;6():49-49.</p><p>Published online 16 Jul 2007</p><p>PMCID:PMC1939711.</p><p></p>nes of the tumor (T) and normal (P) group analyzed by bisulfite sequencing. For each clone the methylation status of analyzed CpG sites is shown (solid circles: methylation, open circles: no methylation). Numbers on x-axis refer to base pair positions as indicated in Figure 1. Asterisks indicate amplicons derived from densely methylated promoters demonstrating at least 11 methylated CpG sites